Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib: in unresectable or metastatic melanoma.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy - 1 Oct 2012

Keating Gillian M

Abstract excerpt

Vemurafenib is a first-in-class, small molecule BRAFV600E inhibitor. It is indicated in the US for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation, and in the EU as monotherapy in adults with BRAFV600 mutation-positive unresectable or metastatic melanoma. Oral vemurafenib improved overall survival (OS) [co-primary endpoint] in patients with unresectable, previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Indoles
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Skin Neoplasms

Share to Sulfonamides

Share to Survival Rate

Share to Vemurafenib

Source

Identifiers

PMID: 22946753
DOI: 10.2165/11209860-000000000-00000

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib: in unresectable or metastatic melanoma.PMID 22946753Read ↗

Vemurafenib: a guide to its use in unresectable or metastatic melanoma.Semantic proximity Read ↗

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.Semantic proximity Read ↗

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.Semantic proximity Read ↗

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.Semantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Semantic proximity Read ↗

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.Semantic proximity Read ↗

Vemurafenib. Value unclear in metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.